Benfluorex HCl | CAS#23642-66-2 | anorectic and hypolipidemic agent

MedKoo Cat#: 596291 | Name: Benfluorex HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Benfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine.. Two clinical studies have shown it may improve glycemic control and decrease insulin resistance in people with poorly controlled type 2 diabetes.

Chemical Structure

Benfluorex HCl

CAS#23642-66-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 596291

Name: Benfluorex HCl

CAS#: 23642-66-2 (HCl)

Chemical Formula: C19H21ClF3NO2

Exact Mass: 387.1213

Molecular Weight: 387.82

Elemental Analysis: C, 58.84; H, 5.46; Cl, 9.14; F, 14.70; N, 3.61; O, 8.25

Price and Availability

Size	Price	Availability	Quantity
5g	USD 450.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

23602-78-0 (free base) 23642-66-2 (HCl)

Synonym

Benfluorex HCl; Benfluorex hydrochloride; Lipophoral; Mediator; JP 992; EINECS 245-801-8; Mediaxal; Balans; EINECS 245-020-2;

IUPAC/Chemical Name

2-((1-(3-(trifluoromethyl)phenyl)propan-2-yl)amino)ethyl benzoate hydrochloride

InChi Key

NLOALSPYZIIXEO-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H20F3NO2.ClH/c1-14(12-15-6-5-9-17(13-15)19(20,21)22)23-10-11-25-18(24)16-7-3-2-4-8-16;/h2-9,13-14,23H,10-12H2,1H3;1H

SMILES Code

O=C(OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1)C2=CC=CC=C2.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Benfluorex hydrochloride is a hepatic nuclear factor 4 alpha (HNF4α) activator.

In vitro activity:

Benfluorex had an inhibitory activity on the incorporation of 14C-acetate and of 14C-HMG-CoA into non-saponifiable lipids in human blood mononuclear cells incubated in lipid-deficient medium. The lack of effect on the incorporation of 14C-mevalonate into non-saponifiable lipids strongly suggested that the reduction of sterol biosynthesis was mainly due to the inhibition of HMG-CoA reductase activity. Reference: Drugs Exp Clin Res. 1986;12(11):923-7. https://pubmed.ncbi.nlm.nih.gov/3816510/

In vivo activity:

The effect of chronic (20 days) oral administration of benfluorex (35 mg/kg) in a rat model of NIDDM, induced by injection of STZ 5 days after birth and characterized by frank hyperglycemia, hypoinsulinemia, and hepatic and peripheral insulin resistance, was examined. Basal blood glucose and insulin levels, glucose tolerance and glucose-induced insulin release in vivo, and basal and insulin-stimulated in vivo glucose production and glucose utilization were examined. In the benfluorex-treated diabetic rats, postabsorptive basal plasma glucose levels were decreased (8.1 +/- 0.2 mM compared with 10.5 +/- 0.5 mM in the pair-fed untreated diabetic rats and 6.1 +/- 0.2 mM in the benfluorex-treated nondiabetic rats), whereas the basal and glucose-stimulated intravenous glucose tolerance test plasma insulin levels were not improved. In the pair-fed untreated diabetic rats, the basal glucose production and overall glucose utilization were significantly increased. In the benfluorex-treated diabetic rats, the basal glucose production and basal overall glucose utilization were normalized. After hyperinsulinemia, glucose production was normally suppressed, whereas overall glucose utilization was not significantly improved. Reference: Diabetes. 1993 Apr;42(4):564-70. https://diabetes.diabetesjournals.org/content/42/4/564.long

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	257.85
	Water	3.3	8.59

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 387.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Sommariva D, Blasi F, Cosentini R, Berruto M. Effects of benfluorex on sterol biosynthesis in incubated human blood mononuclear cells. Drugs Exp Clin Res. 1986;12(11):923-7. PMID: 3816510. 2. Serradas P, Blondel O, Bailbe D, Portha B. Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. Diabetes. 1993 Apr;42(4):564-70. doi: 10.2337/diab.42.4.564. PMID: 8454107.

In vitro protocol:

1. Sommariva D, Blasi F, Cosentini R, Berruto M. Effects of benfluorex on sterol biosynthesis in incubated human blood mononuclear cells. Drugs Exp Clin Res. 1986;12(11):923-7. PMID: 3816510.

In vivo protocol:

1. Serradas P, Blondel O, Bailbe D, Portha B. Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. Diabetes. 1993 Apr;42(4):564-70. doi: 10.2337/diab.42.4.564. PMID: 8454107.

1: Barrio M, Maccaroni E, Rietveld IB, Malpezzi L, Masciocchi N, Céolin R, Tamarit JL. Pressure-temperature state diagram for the phase relationships between benfluorex hydrochloride forms I and II: a case of enantiotropic behavior. J Pharm Sci. 2012 Mar;101(3):1073-8. doi: 10.1002/jps.22821. Epub 2011 Nov 18. PubMed PMID: 22102487.